RxDoctor Payments Data

Roger Gaddy, MD

Family Medicine · Winnsboro, SCNPI 1669495917

Payments from drug & device makers

$5,113in general payments, 2019–2025

Across 317 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$647
  • AbbVie$549
  • AstraZeneca$469
  • Dexcom, Inc.$422
  • Amgen$416
  • Lilly USA, LLC$330
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$5,113100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,113 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$207,589
Medicare patients
597
Services billed
12,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$133,347
EliquisApixaban100$85,422
MounjaroTirzepatide46$79,556
JardianceEmpagliflozin51$43,333
JanuviaSitagliptin Phosphate44$28,089
XareltoRivaroxaban32$27,081
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$23,700
EntrestoSacubitril/Valsartan26$23,201
TrulicityDulaglutide17$22,832
Bydureon BciseExenatide Microspheres17$20,503
VraylarCariprazine Hcl11$15,190
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$15,096
FarxigaDapagliflozin Propanediol19$13,804
Repatha SureclickEvolocumab24$12,455
ShingrixVaricella-Zoster Ge/As01b/Pf46$10,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$647$133,347127 claims
Lilly USA, LLCMounjaro, Trulicity$330$102,38863 claims
PfizerEliquis$241$85,422100 claims
Boehringer IngelheimJardiance$151$43,33351 claims
GSKTrelegy Ellipta, Shingrix$184$34,04281 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$469$33,00344 claims
MerckJanuvia$74$28,08944 claims
Johnson & JohnsonXarelto$158$27,08132 claims
NovartisEntresto$194$23,20126 claims
AbbVieVraylar, Linzess$549$21,87222 claims
Astellas Pharma US IncMyrbetriq$13$4,85511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Winnsboro

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →